Agoracom Blog Home

Posts Tagged ‘Covid19 testing’

Empower Clinics $CBDT.ca $EPWCF Partners with Leading U.S. Digital Marketing Agency to Launch Direct-to-Consumer e-Commerce Solutions $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 8:19 AM on Thursday, April 8th, 2021

Snow Agency recognized as #1 U.S. digital marketing agency

  • Announced a partnership with Snow Agency to launch its direct-to-consumer (DTC) e-commerce solutions.
  • Snow Agency is a performance digital marketing and creative agency whose customized brand strategies and content production maximize the impact of direct response ads and creatives on Facebook/Instagram, Google/YouTube, Snapchat, and Email/SMS
  • Collaboration will allow Empower patients, existing and prospective, to benefit from an accessible, seamless and educative experience when purchasing at-home diagnostics test kits

VANCOUVER BC / April 8, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens – today announced a partnership with Snow Agency to launch its direct-to-consumer (DTC) e-commerce solutions.

The Snow Agency is a performance digital marketing and creative agency whose customized brand strategies and content production maximize the impact of direct response ads and creatives on Facebook/Instagram, Google/YouTube, Snapchat, and Email/SMS. To date, they’ve brought in more than $250 million USD in sales for their clients. The Snow Agency has been recognized on Yahoo! Finance ranked as the #1 US Digital Marketing Agency & Digital Agency in January 2021 by Design Rush, a top B2B marketplace connecting brands with agencies.

The collaboration will allow Empower patients, existing and prospective, to benefit from an accessible, seamless and educative experience when purchasing at-home diagnostics test kits. Today patients can purchase at-home COVID-19 saliva test kits by phone or email at www.kaitests.com.

“Empower is committed to make our solutions as convenient as possible to all patients in North America. A DTC e-commerce solution is a key part of that solution.” said Steven McAuley, Chairman & CEO of Empower. “I am privileged to now count Snow Agency as a partner in our journey to deliver at-home testing solutions and empower patients to take control of their own health data. Even with vaccines, ongoing testing is desperately needed because more testing, along with mask-wearing and physical distancing, will get people back into offices, planes and classrooms and help catch cases that go undetected”.

“This partnership is really making a positive difference in people’s lives. We know that we can reach millions of consumers with success for brands. We see our partnership with Empower as our contribution from Snow Agency to help reopen the economy, allow people to travel with confidence and getting back to normal life.” said Dan Snow, CEO and Co-founder of Snow Agency.

“As a trained physician and a digital marketing entrepreneur, I fully believe in Empower’s at-home diagnostic testing solutions especially its integrated laboratory services at Kai Medical. It’s the time now to digitally transform healthcare, focus on accessibility and convenience for patients and save valuable time and money on stretched public health services. People will need to get tested regularly so we can all get back to normal” said Dr. Jonathan Snow, COO and Co-founder of Snow Agency.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley CEO
[email protected]
604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Empower Clinics $CBDT.ca $EPWCF Reports Q1 2021 Patient Results With Year Over Year Growth of 460% $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:57 AM on Wednesday, April 7th, 2021

Patient count for March increased by 388%

  • Announced that patient counts increased by 460% in Q1 2021 (26,317) versus Q1 2020 (5,717).
  • Patient counts for the month of March increased by 388% versus the same period in 2020 with total patient counts of 8,379 in March 2021 compared to 2,160 in March 2020.

VANCOUVER BC / April 7, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce that patient counts increased by 460% in Q1 2021 (26,317) versus Q1 2020 (5,717). Patient counts for the month of March increased by 388% versus the same period in 2020 with total patient counts of 8,379 in March 2021 compared to 2,160 in March 2020.

“The delivery of world-class patient care is the number one priority for our team in all the markets we serve.” said Steven McAuley, Chairman & CEO of Empower. “I am so proud of our members’ daily effort and dedication to patients even in such uncertain times. For our team to achieve such significant year-over-year growth numbers is a testament to our ability to execute on our business plan to acquire patients and drive long-term shareholder value. I’m especially proud of the strong growth in the last month of Q1 which sets us up for continued growth in Q2 2021”

The Company has also issued a total of 800,000 stock options priced at $0.57 CAD to investor relation service providers and to a Director of the Company.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Source: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/758635-empower-clinics-reports-q1-2021-patient-results-with-year-over-year-growth-of-460/messages/2311070#message

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Participates In U.S. Federal Government RFP Bids To Test In Excess Of 50,000 Employees Using FDA Approved KAI Saliva COVID-19 At Home PCR Test $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 7:45 AM on Wednesday, March 24th, 2021
  • Announced the submission of bids on 5 significant US Federal Government Requests For Proposal to test in excess of 50,000 Federal employees using the Company’s KAI Medical COVID-19 Saliva Test
  • KAI Saliva is an FDA EUA authorized Saliva COVID-19 RT-PCR Test
  • In addition, RPF bids for over 10,000 of the approximate 50,000 employees are for ongoing testing, representing potential for significant recurring test revenues.

KAI Lab R&D, Development And Delivery Of KAI Saliva At-Home Test Kit Program, Along With Tripling Of KAI Lab Facility, Proves Valuable By Providing Empower With Ability To Bid and Accommodate Successful RFPs

VANCOUVER, BC / March 24, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce the submission of bids on 5 significant US Federal Government Requests For Proposal (“RFP” or “RFPs”) to test in excess of 50,000 Federal employees using the Company’s KAI Medical COVID-19 Saliva Test (“KAI Saliva”). KAI Saliva is an FDA EUA authorized Saliva COVID-19 RT-PCR Test.

In addition, RPF bids for over 10,000 of the approximate 50,000 employees are for ongoing testing, representing potential for significant recurring test revenues.

RFP BIDS INCLUDE FDA ITSELF, AIRPORT, SCHOOLS AND OTHER FACILITIES ACROSS THE COUNTRY

Empower has submitted US Government RFP bids for the following groups:

1. FDA – Food & Drug Administration

  • All Employees and contractors nationwide
  • Kai Saliva at-home test kit program
  • In excess of 38,000 kits required

2. Hanover County, Virginia Government

  • Public Schools
  • Regional Jail
  • Regional Library
  • 5,000 employees – Ongoing Testing
  • Kai Saliva at-home test kit program
  • Rapid antigen testing kits

3. Scranton, Pennsylvania Airport

Onsite testing facility for:

  • RT-PCR testing
  • Rapid Testing
  • Saliva RT-PCR testing
  • Ongoing testing

4. Alameda County, California

  • 3,100 employees and contractors – ongoing testing
  • Kai Saliva at-home test kit program

5. Durham County, North Carolina

  • 2,000 employees and contractors – ongoing testing
  • Kai Saliva at-home test kit program

RFP’S STEM FROM BIDEN ADMINISTRATION TO INVEST MORE THAN $12 BILLION TO EXPAND COVID-19 TESTING

These measures are part of President Biden’s strategy to increase COVID-19 testing nationwide as vaccinations increase.

As part of President Biden’s National Strategy for the COVID-19 Response and Pandemic Preparedness, the U.S. Department of Health and Human Services (HHS) will invest $10 billion from the American Rescue Plan to ramp up screening testing to help schools reopen, $2.25 billion to scale up testing in underserved populations, and provide new guidance on asymptomatic screening testing in schools, workplaces, and congregate settings.

Empower Clinics is ideally positioned with the right products.

KAI LAB AND KAI SALIVA COVID-19 PCR TEST COMPETITIVE ADVANTAGES IN RFP BIDS

Empower’s KAI Medical COVID-19 Saliva Test (“KAI Saliva”) is an FDA EUA authorized Saliva COVID-19 RT-PCR Test that includes the following meaningful competitive advantages

  • KAI Salvia is an at-home based, self-administered COVID-19 RT-PCR saliva test kit that is easily accessed and self-administered. Visit www.kaitests.com
  • KAI Saliva provides travelers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into the United States or arriving in other countries that have strict executive travel orders.
  • KAI Saliva can provide major airlines and the tourism sector with the ability to provide solutions for travelers by making a KAI Saliva test as part of the ticketing purchase, the check-in process, in a kiosk, or on an e-commerce website.
  • As a result of continued rapid growth in 2021, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company then revised this planned expansion upwards on February 16th when it announced “KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1.”

As a result of these competitive advantages, Empower believes the integrated solution of KAI Lab and KAI Saliva makes for a very strong offering.

“Our decision to triple the size of Kai Labs was in anticipation of positioning Kai Labs for growth and to be able bid on many significant U.S. Government contracts that are being awarded” said Steven McAuley, Chairman & CEO. “With investment in R&D and having substantial working capital available, I believe Kai Labs is deserving of national attention and has as a real opportunity to win these type of bids. Our new Kai Saliva test kit is in high demand and we are seeing more and more bids specifically requesting saliva-based COVID-19 testing products.”

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley CEO
[email protected]
604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Empower Clinics $CBDT.ca $EPWCF Announces Receipt of Over $12,000,000 From Exercise of Warrants, Receives Full MDEL Status from Health Canada, Finalizes Lease Agreements for Initial Canadian Health Centers and Completes Lease for KAI Lab Expansion $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:36 AM on Friday, March 19th, 2021
  • Receipt of over $12M from exercise of warrants
  • Received Full MDEL Status
  • Finalizing leases for initial Canadian Health Centers
  • KAI Lab Expansion

Warrant Proceeds and Continued Business Development on Multiple Fronts Positions Empower for Continued and Rapid Growth in 2021

VANCOUVER, BC / March 19, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to provide a comprehensive corporate update with respect to the following matters:

RECEIPT OF OVER $12,000,000 FROM THE EXERCISE OF WARRANTS

Empower is pleased to announce the receipt of in excess of $12,000,000 from the exercise of warrants up to March 18, 2021, representing an increase of approximately $1,500,000 since the Company’s announcement on March 4, 2021 when the Company announced the receipt of approximately $10,500,000.

The receipt of these warrant proceeds, along with the Company’s expectations of generating continued significant revenue from its KAI Medical Laboratory, as well as, anticipated significant revenue from its national Canadian clinic launches and test kit sales over the next 12 months, provides Empower with the war chest necessary for continued rapid expansion in each of its divisions.

Steven McAuley, Chairman and CEO of Empower stated “Theodore Roosevelt said credit belongs to…who is actually in the arena, whose face is marred by dust and sweat…, I can attest that I am in the arena, our team members are in the arena, all focused, working hard for our shareholders, ensuring we continue to grow and reach new heights.” Mr. McAuley goes on to say “The company has never looked better, has never been more stable than today, has a great balance sheet and has clear vision for the future. Our leadership team, our entire team share a collective vision of growth, we care about patients, we are focused on technology, we understand the importance of what we are doing.”

RECEIPT OF FULL MEDICAL DEVICE ESTABLISHMENT LICENCE (MDEL) APPROVAL STRENGTHENS ABILITY TO SELL AND DISTRIBUTE KAI SALIVA AT-HOME COVID-19 RT-PCR TEST IN CANADA AND OTHER APPROVED TESTING PRODUCTS GOING FORWARD

Empower’s KAI Medical COVID-19 Saliva Test (“KAI Saliva”) is an FDA EUA and Health Canada authorized at-home Saliva COVID-19 RT-PCR Test. KAI Saliva provides travelers, both foreign and domestic with a simple, fully compliant method to obtain an RT-PCR test and test result prior to arriving or coming back into Canada or arriving in other countries that have similar executive travel orders.

On January 21, 2021 Empower announced the filing of an MDEL for the purposes of importing, distributing and selling KAI Saliva which has experienced immediate success upon its launch on December 15, 2020 in the United States, with an initial soft launch order of 5,000 units and an order for the next 25,000 KAI Saliva PCR Test Kits with a sales value of approximately $5.5M.

On March 8, 2021 Empower announced it anticipates an order for the next 50,000 KAI Saliva test kits to prepare for demand.

Our MDEL can now be found on the Government of Canada MDEL ‘Live Listings’ page.

“We all have an urgent requirement for a home-based, self-administered COVID-19 saliva test kit that can help open up the economy and facilitate travel that meets the requirements of the executive travel orders.” said Steven McAuley, Chairman & CEO. “As a result of receiving full MDEL status, Empower is engaged in meaningful discussions with several potential distribution partners across Canada. We fully expect KAI Saliva to enjoy the kind of success it is achieving in the United States.”

KAI Saliva can provide major airlines, cruise lines and the tourism sector with the ability to provide solutions for travelers by making a KAI Saliva purchase part of the ticketing purchase, the check-in process, in a kiosk, or on an e-commerce website.

NEGOTIATED LEASE AGREEMENTS FOR FIRST THREE HEALTH CENTRE LOCATIONS WITH BUILD OUT TO COMMENCE IN Q2 2021

On February 25, 2021 Empower announced the locations of the first three integrated health centers in Ontario, with each location anticipated to generate on average approximately $3,000,000 in annualized revenue, as follows:

1) Etobicoke, Ontario Approximately 2,700 sq.ft

2) London, Ontario Approximately 3,100 sq.ft

3) Etobicoke, Ontario Approximately 2,900 sq.ft

Empower is now advancing to the build-out phase with first completions and openings anticipated for 2Q 2021. Advanced discussions are currently underway on multiple additional locations as the Company advances the rollout of its national clinic expansion strategy.

Empower will be opening primary care, plus para-medical healthcare services in each of the locations, with a target of four (4) to six (6) Medical Doctors (MD) and four (4) to six (6) paramedical practitioners per location.

When each location is fully operational, Empower anticipates it can generate $2,560,000 – 3,600,000 in annual revenue per location.

COMPLETION OF LEASE AGREEMENT FOR KAI MEDICAL LABORATORY EXPANSION

KAI Medical Laboratory (“KAI LAB”), a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI LAB experienced significant growth in its first quarter under Empower (October 2020 – December 2020), with Q4 COVID-19 test units exceeding 6,000, far surpassing the 1,300 total units prior to acquisition.

Furthermore, on March 8, 2021, Empower announced KAI LAB had achieved the following significant milestones in 2021:

1. Each of January and February 2021 were record months for specimen collection and processing, with February delivering sequential growth of 27% over January 2021.

2. Exceeded single day specimen processing of 1,000 + units in February.

3. As a result of record months year to date 2021, the KAI LAB annual revenue run rate is now exceeding $10,000,000 with meaningful positive cash flow

As a result of this continued rapid growth in 2021, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company then revised this planned expansion upwards on February 16th when it announced “KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1.”

KAI LAB has now completed the lease amendment with the landlord to take over the neighboring tenants’ space to triple the size of KAI LAB. Tenant’s improvements are set to commence immediately and before the end of March 2021. The expansion work will enable KAI LAB to hire additional staff across a wide array of roles, all to improve operational efficiency and to meet anticipated demand over the coming weeks and quarters.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across the US and Canada. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
CEO

CONTACTS:

Steven McAuley CEO
[email protected]
604-789-2146

Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Annual Revenue Run Rate Now Exceeding $10,000,000 USD. Empower Anticipates Order For Next 50,000 KAI Saliva PCR Test Kits To Prepare For Demand $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 9:03 AM on Monday, March 8th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs, science and R&D, is now tripling in size.

  • Each of January and February 2021 recorded record months for specimen collection, with February delivering sequential growth of 27% over January 2021.
  • Exceeded a single day specimen processing of 1,000 + units in February.
  • As a result of record months year to date 2021, the KAI LAB annual revenue run rate is now exceeding $10,000,000 with meaningful positive cash flow.

VANCOUVER, BC / ACCESSWIRE / March 8, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (EPWCF:OTCQB) (8EC:Frankfurt) (“Empower” or the “Company“) an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens is pleased to announce our KAI Medical Laboratory (“KAI LAB”) has achieved the following significant milestones:

1. Each of January and February 2021 recorded record months for specimen collection, with February delivering sequential growth of 27% over January 2021.

2. Exceeded a single day specimen processing of 1,000 + units in February.

3. As a result of record months year to date 2021, the KAI LAB annual revenue run rate is now exceeding $10,000,000 with meaningful positive cash flow.

Finally, the successful launch of our KAI Saliva PCR Test (“KAI Saliva”) generated an initial soft launch of 5,000 units, leading to the order of 25,000 additional units with a sales value of approximately $5,500,000 on January 7, 2021. Empower now anticipates placing an order for 50,000 additional KAI Saliva units with a retail sales value of approximately $11,000,000 to build inventory sufficient to meet current demand in both the United States and Canada.

KAI MEDICAL LABORATORY NOW EXPANDING TO TRIPLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED GROWTH

KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI LAB experienced significant growth in its first quarter under Empower (October 2020 – December 2020), with Q4 COVID-19 test units exceeding 6,000, far surpassing the 1,300 total units prior to acquisition.

As a result, on January 21st, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company then revised this planned expansion upwards on February 16th when it announced “KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1.”

Expansion work is commencing in March 2021 to enable KAI LAB to hire additional staff across a wide array of roles, all to improve operational efficiency and to meet anticipated demand over the coming weeks and quarters.

“Kai Medical Laboratory with the leadership of Yoshi Tyler have surpassed our initial growth forecasts, have demonstrated disciplined work ethic, a focus on science with a passion for operational excellence.” said Steven McAuley, Chairman and CEO of Empower “Kai Medical is developing into a national brand with the potential to positively impact healthcare outcomes by providing access to numerous testing protocols that go beyond COVID-19 in the future.”

For the purposes of facilitating the expansion, Empower has already secured additional space next door to KAI LABS in order to separate the lab & science from logistics, admin and customer support. Materials handling staff is being added to process the intake of thousands of packages per day.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/756801-empower-clinics-kai-medical-laboratory-annual-revenue-run-rate-now-exceeding-10-000-000-usd-empower-anticipates-order-for-next-50-000-kai-saliva/messages/2307028#message

VIDEO – Empower Clinics $CBDT.ca $EPWCF CEO Answers Shareholder Questions In Q&A $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 4:04 PM on Friday, March 5th, 2021

On behalf of Steve and the Empower Clinics team, we are happy to present this Empower Clinics Shareholder Q&A.   

Thanks to all investors that posted their questions here on AGORACOM. 

Enjoy this powerful video.

Empower Clinics $CBDT.ca $EPWCF Announces Locations of First Three Integrated Health Centres in Ontario. Each Location Anticipated to Generate Approximately $3,000,000 In Revenue. Further Locations to Be Announced $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:01 AM on Thursday, February 25th, 2021

Launch Confirms Empower Stated Strategy To Execute National Clinic Expansion Following Canadian Clinics Acquisition And Partnership Announcements in 2021

  • Announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue.
  • Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.

VANCOUVER, BC / February 25, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue. Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.

THREE ONTARIO LOCATIONS AND TWELVE PHYSICIANS COMMITTED TO OPEN

The locations and approximate sizes of the integrated health centres are as follows:

1) Etobicoke, Ontario Approximately 2,700 sq ft.

2) London, Ontario Approximately 3,100 sq ft.

3) Etobicoke, ON (site two) Approximately 2,900 sq ft.

“Dr. Aviv Tsimmerman and Dr. Jordan Rabinowitz are executing on our growth initiatives, they are achieving milestones, they are opening our healthcare centers.” said Steven McAuley, Chairman & CEO. “Our approach is based on patients and their needs, the delivery of care, an improved healthcare model, that provides advanced technology and access for an improved healthcare outcome.”

Each location is expected to host 4-6 physicians. Empower has already secured commitments from twelve (12) physicians to date, with numerous additional medical doctors and para-medical practitioners expressing interest to join the team.

“Having a strategic blend of health professionals allows us to provide an unparalleled integrative healthcare experience.” stated Dr. Jordan Rabinowitz, Chief Operating Officer. He further states, “This defines our path to assist millions of Canadians nationwide.”

HEALTH CARE SERVICES TO BE DELIVERED AND ANTICIPATED REVENUE MODEL

Empower will be opening primary care, plus para-medical healthcare services, with a target of four (4) to six (6) medical doctors and four (4) to six (6) paramedical practitioners per location.

Primary care services include:

  • Family physicians
  • Walk-in physicians
  • Tele-medicine and virtual care

Empower expects to generate $400,000 – $600,000 in annual revenue per MD, per location, which equates to a revenue range between $1,600,000 – $2,400,000 annually per location.

Paramedical services include:

  • Chiropractic
  • Physiotherapy
  • Registered Massage Therapy
  • Chiropody
  • Acupuncturists
  • Osteopaths
  • Nutritionists

Empower expects to generate $960,000 – $1,200,000 in annual revenue per location.

Together, when each location is fully operational, Empower expects to generate $2,560,000 – $3,600,000 in annual revenue per location.

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

  • Dermatology
  • Cardiology

Empower is currently in advanced discussions with potential partners in each of these specialty areas and believes they hold the potential to add significant value to the operations of each healthcare centre.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

Read more: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/756054-empower-clinics-announces-locations-of-first-three-integrated-health-centres-in-ontario-each-location-anticipated-to-generate-approximately-3m/messages/2305329#message

VIDEO – As Empower Clinics $CBDT.ca $EPWCF Makes New Highs On Multiple Major Announcements, CEO McAuley Discusses Why $100M Clinic Revenue Is Stage 1 – And Much More Is Coming $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 5:27 PM on Thursday, February 18th, 2021

When we conduct a “Beyond The Press Release” interview, it is always about A press release …. but Empower Clinics has been moving so fast that we sat down with CEO Steve McAuley to discuss these THREE press releases, the explosive growth of the Company and where it is going:

  • Partnership With Rexall To Launch Integrated Health Centres
  • Surpassed 1,000 COVID-19 tests on 1 day for first time ever … 3X Lab Expansion
  • Secured Medical Device Establishment License (MDEL) To Sell KAI Saliva

As usual, Six Sigma Steve McAuley doesn’t disappoint as he confidently and clearly tells investors where Empower Clinics is going next.

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Demonstrates Significant Scientific Capability by Validating its PCR Tests Accurately Detect COVID-19 U.K. and South Africa Variants $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:31 AM on Thursday, February 18th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and travel industry

  • Announced KAI Medical Laboratory has validated that its various COVID-19 PCR test products are able to accurately detect the B.1.1.7 (UK variant) & B.1.351 (South African variant)

VANCOUVER BC / February 18, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce our KAI Medical Laboratory (“KAI LAB”) has validated that its various COVID-19 PCR test products are able to accurately detect the B.1.1.7 (UK variant) & B.1.351 (South African variant).

“The Kai Labs motto of Inspire by Science, Built on Integrity is displayed so accurately as the team of molecular scientists took it upon themselves to validate our test protocols against pervasive new COVID-19 variants.” said Steven McAuley, Chairman & CEO. “Leading with science, continuous improvement and a desire to impact healthcare outcomes elevates Kai Labs to a national and international stage. I expect this to be a competitive advantage as we endeavour to sign new global distribution and sales contracts.”

World Health Organization (WHO) Chief Scientist Confirms The U.K. Variant and South African Variants Are a Concern

Dr. Soumya Swaminathan comments “…scientists have now studied this and have found that these variants do tend to spread faster, they’re more transmissible or more infectious. So that’s the worrying part.”

KAI Medical Laboratory Research & Development a key differentiator for the Future

The KAI Lab testing protocol tests for parts of the viral genome that is not affected by the mutations in the spike protein the “S’ gene. In effect, this ensures the active virus in a patient’s RNA genetic sequence can be detected and a correct test result will be provided.

Dr. Soumya Swaminathan indicates “We know that testing, that identifying those who are infectious, that being able to provide them supportive isolation, tracking and contact tracing, and quarantining all the contacts…All of these things together definitely make a difference in bringing down transmission.”

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755571-empower-clinics-kai-medical-laboratory-demonstrates-significant-scientific-capability-by-validating-its-pcr-tests-accurately-detect-covid-19-u-k/messages/2304168#message

Empower Clinics $CBDT.ca $EPWCF KAI Medical Laboratory Surpasses 1,000 COVID-19 Tests in A Day for The First Time Ever. KAI Laboratory Now Tripling in Size in Anticipation of Test Volumes by End of Q1 $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:47 AM on Tuesday, February 16th, 2021

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and travel industry

  • Announced KAI Medical Laboratory (“KAI LAB”) has exceeded 1,000 COVID-19 test units in a single day for the first time.
  • As a result, Empower is announcing that KAI LAB will undergo an even larger expansion in anticipation of projected growth in COVID-19 test requirements in the U.S., Canada and international markets.

VANCOUVER BC / February 16, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce our KAI Medical Laboratory (“KAI LAB”) has exceeded 1,000 COVID-19 test units in a single day for the first time.

As a result, Empower is announcing that KAI LAB will undergo an even larger expansion in anticipation of projected growth in COVID-19 test requirements in the U.S., Canada and international markets.

KAI MEDICAL LABORATORY NOW EXPANDING TO TRIPLE CURRENT SIZE IN ANTICIPATION OF ANTICIPATED RAPID TEST GROWTH

KAI Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, TX was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and the travel industry. KAI experienced significant growth in its first quarter under Empower (October 2020 – December 2020), with Q4 COVID-19 test units exceeding 6,000 specimens processed, far surpassing the less than 1,000 total monthly units prior to acquisition.

As a result, on January 21st, Empower announced “Doubling KAI Medical Laboratory In Anticipation Of Test Volumes By End Of Q1.” The Company is revising this planned expansion upwards by announcing KAL LAB is now expanding by tripling its current size in anticipation of projected growth in COVID-19 test requirements.

Empower Clinics Chairman & CEO, Steven McAuley stated “Today marks a significant milestone for Empower and our shareholders. When we first acquired KAI Medical Laboratory just over four months ago, it was processing less than 1,000 specimens monthly up to that point. Today, we are announcing that KAI has surpassed 1,000 units in a day for the first time ever. This is a credit to both Yoshi Tyler, President KAI LAB and her fantastic team, supported by our business development and marketing strategies which, quite frankly, are still in an early phase. We are just getting started.”

For the purposes of facilitating the expansion, Empower has secured additional space adjacent to KAI LAB in order to separate the lab & science from logistics, admin and customer support. Materials handling staff are being added in anticipation of processing the intake of thousands of packages per day.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

Read More: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/755396-empower-clinics-kai-medical-laboratory-surpasses-1-000-covid-19-tests-in-a-day-for-the-first-time-ever-kai-laboratory-now-tripling-in-size/messages/2303796#message